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Abstract
Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is a rare genetic blood disorder
that leads to abnormal bleeding due to absent capillaries and multiple abnormal blood vessels known as arteriovenous
malformations. A feature of HHT is high-output heart failure due to multiple arteriovenous malformations. High-output
heart failure can lead to recurrent epistaxis Kiesselbach area syndrome (REKAS), further exacerbating heart failure through
increased blood loss and resultant anemia. We report a patient with HHT who presented with high-output heart failure
contributing to REKAS. In patients with REKAS, we propose if anemia is present, REKAS can be avoided by correcting the
anemia by increasing the hemoglobin level to greater than 9 to 10 g/dL. This decreases hyperdynamic circulation and reduces
pressure in the blood vessels of the nose.
Keywords
high-output heart failure, epistaxis, hereditary hemorrhagic telangiectasia, recurrent epistaxis Kiesselbach area syndrome,
anemia

Introduction
Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant blood disorder that is characterized by multiple
telangiectasia (dilated blood vessels in mucous membranes)
and arteriovenous malformations (AVMs), which are direct
connections between arterioles and venules. The prevalence is
approximately 1 in 5000 to 10 000.1 HHT most commonly
manifests as recurrent epistaxis, but it can also manifest as
bleeding in the gastrointestinal, pulmonary, or cerebral circulations.2,3 The typical presentation is epistaxis during puberty,
with cutaneous telangiectasia occurring later in life, usually by
the fourth decade.4 The molecular basis for HHT is a mutation
in the endoglin (ENG) gene or activin receptor-like kinase-1
(ALK1) gene involved in angiogenesis.5 Endoglin is a coreceptor and ALK1 is a receptor for the TGF-beta family.6 A mutation in MADH4, a gene which codes for Smad4, has also been
linked to HHT.7 These 3 genes are part of the TGF-beta superfamily signaling pathway. Endoglin and ALK1 are found in the
vascular endothelium and help maintain vascular integrity;
mutations in these genes lead to vascular dysfunction and the
multiple telangiectasia found in HHT.7,8
The diagnostic criteria used to diagnose HHT, known as
the Curaçao criteria, are listed in Table 1. A definitive diagnosis must include at least 3 of the 4 criteria.9,10

Large vessel involvement, such as pulmonary AVMs, can
occur in 15% to 20% of patients and can lead to high-output
heart failure. The mechanism of action involves the prolonged increase in blood flow from the AVMs, which leads to
changes in the elasticity of the blood vessel walls, leading to
vasodilation and lower systemic vascular resistance. This
ultimately ends with high-output heart failure.11
High-output heart failure is defined by the parameters
found in Table 2. Etiologies of high-output heart failure
include systemic arteriovenous fistulas, hyperthyroidism,
anemia, beriberi, dermatologic disorders (eg, psoriasis),
renal disease, hepatic disease, skeletal disorders (eg, Paget
disease, multiple myeloma), and sepsis.12-14
Recurrent epistaxis Kiesselbach area syndrome (REKAS),
first described in the literature in 1985, refers to the area in
the nasal septum where the anterior and posterior ethmoidal
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Table 1. Curaçao Criteria for Diagnosis of HHT9,10.

Abbreviations: HHT, hereditary hemorrhagic telangiectasia; AVM, arteriovenous malformation.

lungs, respectively. A CT of the sinuses of the head done 4
years prior showed mucosal thickening of the left maxillary
and sphenoid sinus. A previous stress echocardiogram done 3
years prior for an episode of chest pain was negative for ischemia with an ejection fraction of 72%.
During the course of the patient’s hospital stay, she
received a total of 4 units of packed red blood cell transfusions with resolution of her epistaxis with improved hemoglobin from 7.1 g/dL on admission to 9 g/dL on discharge.

Table 2. High-Output Heart Failure Parameters12.

Discussion

1.
2.
3.
4.

Our patient had fulminant signs, and symptoms, of high-output heart failure with worsening and recurrent epistaxis in
the setting of AVMs and acute anemia. She received multiple
units of packed red blood cells, and hematology recommended keeping patient’s hemoglobin at 9 to 10 g/dL. This
eventually resolved the patient’s epistaxis. However, whenever the patient had a decline in hemoglobin to less than 9 g/
dL, she would begin to experience dyspnea and fatigue, and
she would present with recurrent epistaxis.
The basic pathophysiology of high-output heart failure is
an issue with decreased systemic vascular resistance, either
through vasodilation of the systemic vessels or arteriovenous
shunting.12 This leads to decreased blood pressure, which
activates the sympathetic nervous system. Via this mechanism, the heart compensates for the decreased blood pressure
by increasing heart rate and thus cardiac output. Additionally,
the renin-angiotensin-aldosterone (RAA) pathway is activated, leading to water and sodium retention.18 Therefore,
the ejection fraction is still preserved in high-output heart
failure; however, the body is unable to deliver enough oxygen to the tissues, leading to heart failure despite the hyperdynamic circulation.
Even though many peripheral parts of the body receive
decreased blood flow due to systemic vasodilation, the area
of Kiesselbach’s plexus receives extra pressure due to the
increased vascularity of the area and the close proximity to
the pumping force of the heart. Combining the increased
pressure with the thinner and more delicate blood vessels in
the nasal septum leads to an increased risk of recurrent epistaxis2 (Figure 1).
By keeping the patient’s hemoglobin greater than 9 g/dL
would decrease the hyperdynamic circulation by decreasing
the compensatory mechanisms of the heart and decreasing
activation of the RAA pathway. This exerts less pressure on
the thinned and dilated blood vessels of Kiesselbach’s plexus,
leading to resolution of the epistaxis (Figure 2). This was a
relatively easy therapy for this patient, and she was able to be
discharged 2 days after admission with complete resolution
of symptoms.
The causes of high-output heart failure in our patient
include irreversible causes, such as AVMs, and reversible
causes, such as iron-deficiency anemia secondary to blood
loss. Many causes are described in the literature and are

1. Spontaneous recurrent epistaxis
2. Multiple telangiectasia in typical locations (eg, oral mucosa,
palms, nose)
3. Proven visceral AVMs in places such as the gastrointestinal,
pulmonary, or cerebral circulations
4. First-degree family member with HHT

Cardiac output >8 L/min or cardiac index >3.9 L/min/m2
Clinical signs and symptoms of heart failure
Echocardiogram with preserved ejection fraction of >50%
Mixed venous oxygen saturation of >75%

artery, sphenopalatine artery, greater palatine artery, and septal branch of the superior labial artery join to form a vascular
plexus.15,16 Since the area is so vascularized, patients with
HHT are prone to recurrent epistaxis in the region. Blood
vessels appear to be dilated in the Kiesselbach plexus, and
patients may have an anterior septal deformity.17

Case Presentation
A 73-year-old female with a known history of HHT and multiple blood transfusions presented to emergency room with
recurrent and recent worsening of epistaxis. Over the past
week, she had increased shortness of breath with exertion,
and black tarry stools. She denied any chest pain, syncopal
episodes, abdominal pain, nausea, vomiting, or hematemesis. She had a past medical history significant for iron-deficiency anemia and a past surgical history significant for
endoscopic nasal exam with cauterization. She denies
tobacco, alcohol, or illicit drug use. Her family history was
negative for blood disorders. Her home medications included
amlodipine, cyanocobalamin, conjugated estrogen, levothyroxine, and venlafaxine.
The patient was afebrile with a heart rate of 98/min, blood
pressure of 117/72 mm Hg, and respiratory rate of 18/min.
Overall, she appeared weak and pale. Her physical examination demonstrated nares with dried blood; palate, tongue, and
lip telangiectasia; multiple skin telangiectasia; elevated jugular venous pressure up to angle of jaw; grade III/VI systolic
ejection murmur; and bounding peripheral pulses. She also
had bilateral basilar crackles posteriorly and 2+ pedal edema.
Complete blood count showed hemoglobin of 7.1 g/dL
and hematocrit of 24%, with an otherwise normal white
blood cell count and platelet count. Mean corpuscular volume and basic metabolic panel were unremarkable.
Endoscopy done 3 years prior to this admission and a computed tomography (CT) of chest done 2 years prior were consistent with multiple AVMs in the gastrointestinal tract and
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Figure 1. Proposed mechanism of action causing recurrent epistaxis in HHT.

Kiesselbach's plexus in the nose
Absent capillaries in HHT
Dilaon of direct connecons between arterioles and venules in the seng of high-output heart failure
Bleeding through the thinned and dilated blood vessels in the nose
Blood transfusion with packed red blood cells
Hemoglobin level increased with transfusion
Decrease in hyper-dynamic circulaon
Decreased pressure in thin blood vessels of the nose
Resoluon of epistaxis

Figure 2. Proposed mechanism of avoiding REKAS in HIT by correcting anemia.

outlined in Tables 3 and 4. Specifically, our patient had CT
evidence of multiple AVMs. The prolonged increase in
blood flow caused changes in the elasticity of the blood
vessel walls, which led to vasodilation and lower systemic
vascular resistance and thus triggering the high-output
heart failure pathway. The reversible cause of anemia is
related to the physiological changes of the body in response
to decreased oxygenation and tissue perfusion, once again
triggering a compensatory increase in cardiac output and
activation of the RAA pathway. In our patient, packed red
blood cells transfusion increased oxygenation and tissue
perfusion, and lessening the patient’s high-output heart
failure.
Iron-deficiency anemia due to recurrent blood loss (reversible), and AVMs (irreversible), can cause hyperdynamic circulation and high-output heart failure, which, over a period of
time, can trigger REKAS due to dilatation of the Kiesselbach
venous plexus in HHT.12 To date, no standard of treatment has
been described in the literature. Surgical treatments such as
suturing of Little’s area or liver transplantation in HHT are
considered more aggressive and are associated with surgical

risks.25-27 Radiofrequency ablation of Kiesselbach’s plexus
can lead to septal perforation and is not a definitive treatment.28 HHT is associated with increased levels of vascular
endothelial growth factor (VEGF) leading to the development
of multiple telangiectasia and AVMs.29 Bevacizumab, a VEGF
inhibitor, is a most expensive drug and not widely studied to
control epistaxis in HHT, due to rareness of this disease.
Studies have found it to be safe to use in HHT, but it is not
currently approved by the Food and Drug Administration in
the treatment of epistaxis in HHT until more studies are suggestive of actual benefit of a decrease in epistaxis.30-33
Thalidomide, a platelet derived growth factor B stimulator, is
another drug proposed to treat epistaxis and gastrointestinal
bleeding in HHT.34,35 However, thalidomide has a significant
side effect profile of increased fatigue and neuropathy, and
both bevacizumab and thalidomide’s efficacy are not established with Phase 2 clinical trials.29-34 Hence, we propose that
REKAS in HHT can be avoided with correction of the reversible causes of high-output heart failure by correcting the anemia through increasing hemoglobin level to approximately
greater than 9 to 10 g/dL.
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Table 3. Reversible Causes of High-Output Heart Failure and Mechanism of Action12-15,18-21.
Reversible Causes of High-Output Heart Failure
Anemia
Sepsis
Hypercapnea (eg, COPD, connective tissue
disorders, interstitial lung disease)
Hyperthyroidism
Beriberi (thiamine deficiency)
Pregnancy
Obesity
Hepatic disease (eg, cirrhosis)a
Carcinoid syndromea
Myeloproliferative disordersa
Dermatological diseases (eg, psoriasis)

Mechanism
Physiological changes to maintain oxygenation and tissue perfusion, such
as increase in cardiac output and activation of the renin-angiotensinaldosterone pathway
Systemic vasodilation and increased cardiac output
Reduction in systemic vascular resistance
Hyperdynamic circulation via tachycardia and increased cardiac output
Vasodilation
Increased cardiac output and blood volume, placenta acts as arteriovenous
shunt, vasodilation
Increased metabolic activity from excess adipose, causing increase in cardiac
output and blood volume; also element of hypercapnea
Splanchnic vasodilation, decreased systemic vascular resistance
Vasodilation
Increased metabolic demand for tissue perfusion via changes in tissue
metabolism
Increased blood flow to the skin due to cutaneous dilatation

Abbreviation: COPD, chronic obstructive pulmonary disease.
a
May be reversible or irreversible, depending on underlying cause, severity, and treatment prognosis.

Table 4. Irreversible Causes of High-Output Heart Failure and Mechanism of Action12-15,22-24.
Irreversible Causes of High-Output Heart Failure
Systemic arteriovenous fistulas or AVMs
Paget’s disease
Multiple myeloma
McCune Albright syndrome

Mechanism
Prolonged increase in blood flow causes changes in elasticity of the blood vessel
wall, leading to vasodilation and lower systemic vascular resistance
Associated with AVMs, increased metabolic activity of affected bone leading to
increased blood flow to area
Associated with AVMs
Associated with AVMs

Abbreviation: AVM, arteriovenous malformation.

Conclusion
High-output heart failure can lead to REKAS, further exacerbating heart failure through increased blood loss and resultant anemia. To date no standard treatment has been proposed.
If anemia is present, REKAS can be avoided by correcting
the anemia with a target hemoglobin level of nearly 9 to 10
g/dL or greater.
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